ClinicalTrials.gg
CompletedNCT05872620ATTAIN-2Updated Sep 4, 2026Results posted

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

A Phase 3 interventional study of Orforglipron and Placebo in Obesity, Overweight and Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 136 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,613
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
3rd of 22
1,613 · median 324
Started
2023
with 5 others
Phase 3
14 of 22
3 open now
Registered
6th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 3rd largest by enrollment, is one of 6 that started in 2023, is one of 14 in phase 3, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

03

Conditions studied

  • Obesity
  • Overweight
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) ≥27.0 kilogram/square meter (kg/m²).
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
  • Have a diagnosis of Type 2 Diabetes (T2D), with ≥7% (≥53 mmol/mol) to ≤10% (86 mmol/mol) and are on stable treatment for T2D for at least 90 days prior to screening, consisting of:

    • either diet/exercise alone or
    • up to 3 oral antihyperglycemic medications (excluding dipeptidyl peptidase IV inhibitors (DPP-4i) or glucagon-like peptide-1 (GLP-1) receptor agonists (RA).

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.
  • Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening.
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (for example, laser photocoagulation or intravitreal injections of anti-vascular endothelial growth factor inhibitors).
  • Have family (first-degree relative) or personal history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia 2 (MEN2) syndrome.
  • Have had a history of chronic or acute pancreatitis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,613 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received matching placebo capsule orally once daily (QD). Treatment was initiated with placebo corresponding to 1 milligram (mg) equivalent to Orforglipron, with dose escalation every 4 weeks to maintain blinding, and was continued through Week 72, unless dose modification was required.

    Drug: Placebo

  • Experimental
    6 mg Orforglipron QD

    Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 6 mg, which was maintained through Week 72, unless dose modification was required.

    Drug: Orforglipron

  • Experimental
    12 mg Orforglipron QD

    Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 12 mg, which was maintained through Week 72, unless dose modification was required.

    Drug: Orforglipron

  • Experimental
    36 mg Orforglipron QD

    Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 36 mg, which was maintained through Week 72, unless dose modification was required.

    Drug: Orforglipron

Interventions

  • Administered orally

    Also known as: LY3502970

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral antihyperglycemic medications (AHMs) classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline

    Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

    Time frame: Baseline to Week 72

  2. Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline

    Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

    Time frame: Baseline to Week 72

  3. Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline

    Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

    Time frame: Baseline to Week 72

  4. Change From Baseline in Waist Circumference

    Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  5. Change From Baseline in Hemoglobin A1c (HbA1c) %

    * Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  6. Change From Baseline in Fasting Serum Glucose (FSG)

    Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  7. Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<6.5%)

    Percentage of participants who achieved hemoglobin A1c (HbA1c\<6.5%) was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

    Time frame: Baseline to Week 72

  8. Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<7.0%)

    Percentage of participants who achieved hemoglobin A1c (HbA1c\<7%) was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

    Time frame: Baseline to Week 72

  9. Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

    Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  10. Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

    Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  11. Percent Change From Baseline in Fasting Insulin

    * Fasting Insulin is a test used to measure the amount of insulin in the body. * Values represented under "Geometric Least Squares Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.

    Time frame: Baseline, Week 72

  12. Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

    Values represented under "Geometric Least Squares Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.

    Time frame: Baseline, Week 72

  13. Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

    Values represented under "Geometric Least Square Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.

    Time frame: Baseline, Week 72

  14. Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

    The SF-36v2 acute form, (1-week recall version) assesses participants' health-related quality of life on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

    Time frame: Baseline, Week 72

07

Results

Posted Sep 4, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Started630329332322
Received at least one dose of study drug628328331321
Completed552287303302
Not completed78422920
Withdrew: Adverse event5763
Withdrew: Death4042
Withdrew: Pregnancy1001
Withdrew: Lack of efficacy4000
Withdrew: Protocol deviation81032
Withdrew: Withdrawal by subject38201010
Withdrew: Physician decision1110
Withdrew: Lost to follow-up17452

Outcome measures

PrimaryPercent Change From Baseline in Body Weight

Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral antihyperglycemic medications (AHMs) classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight
percent changePlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in Body Weight-2.21 ± 0.215-5.50 ± 0.356-7.78 ± 0.411-10.54 ± 0.466
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -3.28 · 95% CI -4.10 to -2.47
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -5.56 · 95% CI -6.48 to -4.65
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -8.33 · 95% CI -9.34 to -7.32
SecondaryPercentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline

Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline
Percentage of participantsPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline24.449.860.272.8
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 25.43 · 95% CI 18.54 to 32.31
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 35.79 · 95% CI 29.12 to 42.45
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 48.37 · 95% CI 41.95 to 54.80
SecondaryPercentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline

Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline
Percentage of participantsPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline7.023.935.550.1
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 16.92 · 95% CI 11.53 to 22.31
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 28.50 · 95% CI 22.69 to 34.31
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 43.15 · 95% CI 36.86 to 49.45
SecondaryPercentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline

Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline
Percentage of participantsPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline1.97.317.728.4
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 5.42 · 95% CI 2.25 to 8.59
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 15.78 · 95% CI 11.32 to 20.24
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 26.52 · 95% CI 21.27 to 31.76
SecondaryChange From Baseline in Waist Circumference

Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · centimeters
Change From Baseline in Waist Circumference
centimetersPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Waist Circumference-2.67 ± 0.233-5.64 ± 0.394-7.16 ± 0.422-9.16 ± 0.437
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -2.97 · 95% CI -3.87 to -2.07
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -4.49 · 95% CI -5.44 to -3.54
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -6.49 · 95% CI -7.46 to -5.51
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c) %

* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) %
percentage of HbA1cPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Hemoglobin A1c (HbA1c) %-0.14 ± 0.060-1.29 ± 0.069-1.60 ± 0.058-1.79 ± 0.059
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -1.16 · 95% CI -1.34 to -0.98
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -1.46 · 95% CI -1.62 to -1.30
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -1.65 · 95% CI -1.82 to -1.49
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligram per deciliter (mg/dL)Placebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Fasting Serum Glucose (FSG)1.2 ± 1.90-33.0 ± 2.13-41.1 ± 1.69-45.8 ± 1.79
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -34.2 · 95% CI -39.8 to -28.6
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -42.3 · 95% CI -47.3 to -37.3
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -47.0 · 95% CI -52.1 to -41.9
SecondaryPercentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<6.5%)

Percentage of participants who achieved hemoglobin A1c (HbA1c\<6.5%) was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<6.5%)
Percentage of participantsPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<6.5%)10.656.267.575.0
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 45.59 · 95% CI 39.29 to 51.89
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 56.92 · 95% CI 50.83 to 63.01
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 64.42 · 95% CI 58.67 to 70.18
SecondaryPercentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<7.0%)

Percentage of participants who achieved hemoglobin A1c (HbA1c\<7%) was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).

Time frame:
Baseline to Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<7.0%)
Percentage of participantsPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<7.0%)23.070.078.085.1
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 46.99 · 95% CI 40.48 to 53.49
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 55.07 · 95% CI 48.89 to 61.25
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <.001 · Risk difference (rd): 62.08 · 95% CI 56.51 to 67.64
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
millimeters of mercury (mmHg)PlaceboPooled 6 mg/12 mg/36 mg Orforglipron QD
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)-1.48 ± 0.534-4.90 ± 0.414
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -3.43 · 95% CI -4.75 to -2.10
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
millimeters of mercury (mmHg)PlaceboPooled 6 mg/12 mg/36 mg Orforglipron QD
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)-1.39 ± 0.323-1.32 ± 0.261
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron QD · Mixed Models Analysis · p = 0.869 · Ls mean difference (net): 0.07 · 95% CI -0.74 to 0.88
SecondaryPercent Change From Baseline in Fasting Insulin

* Fasting Insulin is a test used to measure the amount of insulin in the body. * Values represented under "Geometric Least Squares Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Fasting Insulin
percent changePlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in Fasting Insulin-8.8 ± 2.54-6.4 ± 2.89-8.3 ± 3.18-18.0 ± 2.91
Statistical analysis
  • Placebo vs 6 mg Orforglipron QD · Mixed Models Analysis · p = 0.530 · Geometric ls mean difference (net): 2.6 · 95% CI -5.4 to 11.4
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = 0.898 · Geometric ls mean difference (net): 0.6 · 95% CI -7.8 to 9.7
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = 0.019 · Geometric ls mean difference (net): -10.0 · 95% CI -17.7 to -1.7
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

Values represented under "Geometric Least Squares Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
percent changePlaceboPooled 6 mg/12 mg/36 mg Orforglipron QD
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)-2.95 ± 1.182-6.41 ± 0.880
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron QD · Mixed Models Analysis · p = 0.018 · Geometric ls mean difference (net): -3.57 · 95% CI -6.43 to -0.61
SecondaryPercent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

Values represented under "Geometric Least Square Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
percent changePlaceboPooled 6 mg/12 mg/36 mg Orforglipron QD
Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)-4.70 ± 1.688-17.59 ± 1.096
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron QD · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -13.52 · 95% CI -17.20 to -9.68
SecondaryChange From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)

The SF-36v2 acute form, (1-week recall version) assesses participants' health-related quality of life on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · T-score
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
T-scorePlaceboPooled 6 mg/12 mg/36 mg Orforglipron QD
Physical Component Score0.42 ± 0.2711.47 ± 0.219
Mental Component Score-0.50 ± 0.270-0.10 ± 0.215
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron QD · Mixed Models Analysis · p = 0.003 · Ls mean difference (net): 1.05 · 95% CI 0.36 to 1.73
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron QD · Mixed Models Analysis · p = 0.249 · Ls mean difference (net): 0.40 · 95% CI -0.28 to 1.07

Adverse events

Collected over Baseline Up to Week 74. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo4/628 (0.6%)55/628 (8.8%)452/628 (72%)
6 mg Orforglipron QD0/328 (0%)24/328 (7.3%)231/328 (70.4%)
12 mg Orforglipron QD4/331 (1.2%)34/331 (10.3%)262/331 (79.2%)
36 mg Orforglipron QD2/321 (0.6%)35/321 (10.9%)255/321 (79.4%)
Most frequent serious events
Showing 10 of 147
Most frequent serious events
EventPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Atrial fibrillationCardiac disorders2/6283/3280/3311/321
Urinary tract infectionInfections and infestations2/6281/3283/3311/321
Coronary artery diseaseCardiac disorders3/6280/3280/3312/321
Myocardial infarctionCardiac disorders1/6280/3282/3312/321
NephrolithiasisRenal and urinary disorders1/6280/3281/3312/321
OsteoarthritisMusculoskeletal and connective tissue disorders1/6282/3280/3310/321
DeathGeneral disorders0/6280/3282/3310/321
CholelithiasisHepatobiliary disorders1/6280/3282/3311/321
DiverticulitisInfections and infestations1/6280/3282/3310/321
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/6280/3282/3310/321
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlacebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
HyperglycaemiaMetabolism and nutrition disorders247/62843/32832/33127/321
NauseaGastrointestinal disorders53/62866/328103/331117/321
DiarrhoeaGastrointestinal disorders94/62870/32882/33188/321
VomitingGastrointestinal disorders24/62842/32867/33174/321
ConstipationGastrointestinal disorders49/62858/32870/33172/321
DyspepsiaGastrointestinal disorders22/62830/32851/33135/321
Decreased appetiteMetabolism and nutrition disorders18/62827/32830/33149/321
EructationGastrointestinal disorders4/62821/32838/33128/321
Upper respiratory tract infectionInfections and infestations55/62825/32832/33133/321
NasopharyngitisInfections and infestations59/62830/32822/33123/321

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Mean56.5 ± 10.956.8 ± 10.456.2 ± 10.558.1 ± 10.856.8 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Female298150155154757
Male332179177168856
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Hispanic or Latino1941029597488
Not Hispanic or Latino4162212292181084
Unknown or Not Reported2068741
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
American Indian or Alaska Native20215
Asian112585554279
Native Hawaiian or Other Pacific Islander32106
Black or African American37211928105
White4422382352281143
More than one race22512645
Unknown or Not Reported1258530
Region of Enrollment
Region of Enrollment(Participants)Placebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Argentina59313128149
Australia3518192092
Brazil91464948234
China47222123113
Czechia74404238194
Germany67343534170
Greece2918161578
India3518181889
South Korea201211952
United States173909089442
Baseline Weight
Baseline Weight(kilogram (kg))Placebo6 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Mean101.19 ± 22.62102.29 ± 22.74102.71 ± 21.3299.78 ± 22.99101.45 ± 22.46
08

Study locations

136 sites
  • Cahaba Research - Pelham
    Pelham, Alabama 35124, United States
  • Novak Clinical Research - Tucson - North La Cholla Boulevard
    Tucson, Arizona 85741, United States
  • Yuma Clinical Trials
    Yuma, Arizona 85364, United States
  • AMCR Institute
    Escondido, California 92025, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, Westlake
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Encore Medical Research
    Hollywood, Florida 33024, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32216, United States
  • South Florida Clinical Research Institute
    Margate, Florida 33063, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Balanced Life Health Care Solutions/SKYCRNG
    Lawrenceville, Georgia 30046, United States
  • Endocrine Research Solutions, Inc.
    Roswell, Georgia 30076, United States
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
  • Pacific Diabetes & Endocrine Center
    Honolulu, Hawaii 96813, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • MedStar Good Samaritan Hospital
    Baltimore, Maryland 21239, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
  • IMA Clinical Research
    Albuquerque, New Mexico 87109, United States
  • Albany Medical College, Division of Community Endocrinology
    Albany, New York 12203, United States
  • Albany Stratton VA Medical Center
    Albany, New York 12208, United States
  • NYC Research INC
    Long Island City, New York 11106, United States
  • Accellacare - Raleigh
    Raleigh, North Carolina 27609, United States
  • Summit Headlands
    Portland, Oregon 97210, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37909, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Soma Clinical Trials
    Denison, Texas 75020, United States
  • Epic Medical Research - DeSoto
    DeSoto, Texas 75115, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Diabetes and Glandular Disease Center
    San Antonio, Texas 78229, United States
  • VIP Trials
    San Antonio, Texas 78230, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • Universal Research Group
    Tacoma, Washington 98405, United States
  • Mautalen Salud e Investigación
    Buenos Aires, Buenos Aires F.D. C1128AAF, Argentina
  • CEMEDIAB
    C.a.b.a., Ciudad Aut C1205AAO, Argentina
  • Instituto Centenario
    CABA, Ciudad Autónoma de Buenos Aire 1204, Argentina
  • Instituto de Investigaciones Clinicas Rosario
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica
    Rosario, Santa Fe Province 2000, Argentina
  • Sanatorio San Martin
    Venado Tuerto, Santa Fe Province 2600, Argentina
  • Centro de Investigaciones Médicas Tucuman
    SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
  • CONEXA Investigacion Clinica S.A.
    Buenos Aires, 1012, Argentina
  • Centro Diabetológico Dr. Waitman
    Córdoba, 5000, Argentina
  • Clínica Universitaria Reina Fabiola
    Córdoba, X50004FHP, Argentina
  • Centro de Diagnóstico y Rehabilitación (CEDIR)
    Santa Fe, 3000, Argentina
  • Emeritus Research
    Botany, New South Wales 2019, Australia
  • The AIM Centre / Hunter Diabetes Centre
    Merewether, New South Wales 2291, Australia
  • Royal Brisbane and Women's Hospital
    Brisbane, Queensland 4029, Australia
  • Core Research Group
    Brisbane, Queensland 4064, Australia
  • Logan Hospital
    Meadowbrook, Queensland 4131, Australia
  • Southern Adelaide Diabetes & Endocrine Services
    Oaklands Park, South Australia 5046, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Austin Health - Repatriation Hospital
    Heidelberg West, Victoria 3081, Australia
  • Baker IDI Heart and Diabetes Institute - Melbourne
    Melbourne, Victoria 3004, Australia
  • Advara HeartCare Joondalup
    Joondalup, Western Australia 6027, Australia
  • Centro de Pesquisa Clinica do Brasil
    Brasília, Federal District 71625-175, Brazil
  • Cendi - Endocrinologia e Diabetes
    Goiânia, Goiás 74230-035, Brazil
  • Instituto Lóbus
    Volta Redonda, Rio de Janeiro 27253-003, Brazil
  • Instituto Méderi de Pesquisa e Saúde
    Passo Fundo, Rio Grande do Sul 99010-120, Brazil
  • Instituto de Pesquisa clinica de Campinas
    Campinas, São Paulo 13060-080, Brazil
  • Centro de Pesquisa Clínica de Marília - CPCLIM
    Marília, São Paulo 17504-072, Brazil
  • Pesquisare Saude
    Santo André, São Paulo 09080-110, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • The Second People's Hospital of Hefei
    Hefei, Anhui 230011, China
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
  • Chongqing General Hospital
    Chongqing, Chongqing Municipality 400014, China
  • ShenZhen People's Hospital
    Shenzhen, Guangdong 518020, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang Shi, Henan 471003, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
  • Jiangsu Province Official Hospital
    Nanjing, Jiangsu 210008, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Nantong First People's Hospital
    Nantong, Jiangsu 226001, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • Dalian Municipal Central Hospital Affiliated of Dalian Medical University
    Dalian, Liaoning 116033, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Tianjin Medical University Zhu Xianyi Memorial Hospital
    Tianjin, Tianjin Municipality, China
  • The First People's Hospital of Yunnan Province
    Kunming, Yunnan 650034, China
  • Milan Kvapil s.r.o., Diabetologicka ambulance Pribram
    Příbram, Central Bohemia 26201, Czechia
  • MUDr. Tomas Edelsberger
    Krnov, Moravskosl 79401, Czechia
  • Diahelp s.r.o
    Pardubice V, Pardubice 530 02, Czechia
  • Dialine - Interni a diabetologicka ambulance
    Pilsen, Plzeň-město 301 00, Czechia
  • Diabet2 s.r.o., diabetologicka a interni ambulance
    Prague, Praha 1 11000, Czechia
  • Milan Kvapil s.r.o., Diabetologicka ambulance
    Prague, Praha 4 14900, Czechia
  • ResTrial s.r.o.
    Prague, Praha 8 18100, Czechia
  • MUDr. Sabina Palova
    Jílové u Prahy, Praha-západ 252 42, Czechia
  • MUDr. Alena Vachova
    České Budějovice, South Bohemian Region 37011, Czechia
  • Nemocnice Cesky Krumlov
    Český Krumlov, 381 01, Czechia
  • Endokrinologie MUDr. Rehorkova s.r.o.
    Hradec Králové, 500 12, Czechia
  • MUDr. Jitka Zemanová - diabetologie a interna s.r.o.
    Pilsen, 326 00, Czechia
  • CDG Studienambulanz Hartard
    München, Bavaria 80809, Germany
  • Gemeinschaftspraxis Dr. med. Josef und Wilma Großkopf
    Wallerfing, Bavaria 94574, Germany
  • Ceda-Research
    Pohlheim, Hesse 35415, Germany

Showing the first 100 of 136 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Horn DB, Shukla AP, Huang H, Twum E, Allen SE, Kis SG. Orforglipron for obesity treatment in older patients >/=65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials. Obes Pillars. 2026 Jul 14;19:100301. doi: 10.1016/j.obpill.2026.100301. eCollection 2026 Sep. PubMed 42577069 ↗
  • Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG, Aberle J, Bain SC, Allen S, Sarker E, Wu Q, Stefanski A, Jouravskaya I; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026 Dec 20;406(10522):2927-2944. doi: 10.1016/S0140-6736(25)02165-8. Epub 2025 Nov 20. PubMed 41275875 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2025, 26 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 26 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
May 24, 2023
StartActual
Jun 5, 2023
Primary completionActual
Aug 8, 2025
CompletionActual
Aug 8, 2025
Results first posted
Sep 4, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05872620
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Jun 5, 2023
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025
Results posted
Sep 4, 2026
Last update
Sep 4, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion